International- French pharmaceutical giant scrapped a plan to give the US priority access to its potential COVID-19 vaccine after a backlash from
France and the EU. - CEO Paul Hudson previously said the US "has the right" to get the vaccine first because they had contributed the most to
Sanofi 's vaccine project. - These remarks were criticized by French Prime Minister Edouard Philippe and President Emmanuel Macron, who said no country should have priority over the drug.
- On Friday, Serge Weinberg, chairman of Sanofi's board of directors, intervened, promising no country would get priority.
- Sanofi has long received funding from the US Biomedical Advanced Research and Development Authority. In February,
BARDA sent an extra $30 million to fund Sanofi's vaccine program. - Visit Business Insider's homepage for more stories.
French pharmaceutical giant Sanofi has reneged on its pledge to give the US priority access to its potential vaccine for the coronavirus following a backlash from the highest levels of French government.
CEO Paul Hudson had said on Wednesday that because the US has spent millions of dollars to support Sanofi's work on a vaccine, it "has the right to the largest pre-order." Sanofi is developing two vaccines, neither of which has been approved for use yet.
Hudson's logic was met with outrage in France, and across the EU.
A vaccine is "a global public good, which is not submitted to market forces," the office of President Emmanuel Macron said on Thursday.
Prime Minister Edouard Philippe echoed those sentiments, tweeting: "Equal access for all to vaccine is not negotiable."
For Philippe, it was also a matter of loyalty to France. "I just reminded Serge Weinberg who chairs Sanofi that this is a great deeply French company," he also said.
On Friday, Weinberg, chairman of Sanofi's board of directors, intervened.
"I am going to be extremely clear: there will be no particular advance for any country," Weinberg told France 2 TV.
Macron had also been "affected" by Hudson's interview, a source told Bloomberg. The Sanofi CEO has been summoned to meet with Macron on May 19.
Sanofi has long received US government funding from the US Biomedical Advanced Research and Development Authority (BARDA).
On February 18, Sanofi announced a new partnership with BARDA, with a new $30 million cash injection to help the search for a vaccine. At the time, Sanofi had already been working on a vaccine by leveraging its research on SARS, another respiratory disease.
Hudson told Bloomberg earlier this week that because the US was first to fund Sanofi's research, it expects "that if we've helped you manufacture the doses at risk, we expect to get the doses first."
As a result of the collaboration with BARDA, Hudson said the US can "expect to get the doses first" in return for its support.
Critics of the arrangement have pointed out that Sanofi benefits from in tax credits from the French state.
The French Socialist Party estimates the French government has saved Sanofi at least 150 million euros ($162 million) in recent years, the BBC reported.
On Thursday, 140 world leaders signed an open letter calling for a vaccine to be universally available and not patented.
"Governments and international partners must unite around a global guarantee which ensures that, when a safe and effective vaccine is developed, it is produced rapidly at scale and made available for all people, in all countries, free of charge," the letter said.
Stefan de Keersmaecker, a spokesperson for the European Commission told Agence France-Presse: "The vaccine against COVID-19 should be a global public good and its access needs to be equitable and universal."
A Sanofi spokesperson told Business Insider's Bryan Pietsch on Wednesday that the company is committed to making its vaccine "accessible to everyone."
Partnering with BARDA "allows [us] to initiate production as early as possible while we continue to develop and register the vaccine," the spokesperson said.
Vaccines would be distributed in areas where they are produced, they added.
Macron said on Thursday that he expects a vaccine to be ready no earlier than Winter 2021.
Read the original article on Business Insider